This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kono, K. Articles by Matsumoto, Y. Search for Related Content PubMed PubMed Citation Articles by Kono, K. Articles by Matsumoto, Y.

Prognostic Significance of Adoptive Immunotherapy with Tumor-associated Lymphocytes in Patients with Advanced Gastric Cancer

A Randomized Trial¹

First Department of Surgery, Yamanashi Medical University, Yamanashi 409-3898, Japan

Purpose: We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved survival effect is observed with AIT.

Experimental Design: Forty-four consecutive patients with stage IV gastric cancer [staged according to the International Union against Cancer classification] were prospectively assigned to the control group (chemotherapy alone) or the AIT group (AIT plus chemotherapy). Patients in the AIT group received an adoptive transfer of cultured TALs in combination with low-dose cisplatinum/5-fluorouracil chemotherapy, whereas patients in the control group received chemotherapy alone.

Results: The 50% survival rates were 11.5 and 8.3 months in the AIT and control groups, respectively. The overall survival of patients in the AIT group was significantly better than that of patients in the control group, as analyzed by the log-rank test (P < 0.05). Multivariate analysis with Cox’s proportional hazards model revealed that AIT provided an independent prognostic factor, indicating that AIT influenced patient survival in a positive manner.

Conclusions: AIT with TALs in combination with chemotherapy was effective in prolonging survival in patients with stage IV gastric cancer.

This article has been cited by other articles:

				S. Y. Chui, T. M. Clay, H. K. Lyerly, and M. A. Morse The Development of Therapeutic and Preventive Vaccines for Gastric Cancer and Helicobacter pylori Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1883 - 1889. [Abstract] [Full Text] [PDF]

				F. Ichihara, K. Kono, A. Takahashi, H. Kawaida, H. Sugai, and H. Fujii Increased Populations of Regulatory T Cells in Peripheral Blood and Tumor-Infiltrating Lymphocytes in Patients with Gastric and Esophageal Cancers Clin. Cancer Res., October 1, 2003; 9(12): 4404 - 4408. [Abstract] [Full Text] [PDF]